scholarly journals Biopolymers as Wound Healing Materials: Challenges and New Strategies

Author(s):  
Ali Demir ◽  
Erdal Cevher
Keyword(s):  
2021 ◽  
Vol 22 ◽  
Author(s):  
Mehmet Evren Okur ◽  
Ece Özcan Bülbül ◽  
Gökçe Mutlu ◽  
Kalliopi Eleftherıadou ◽  
Ioannis D. Karantas ◽  
...  

Background & Objective: Diabetes is a global health problem associated with millions of deaths; the most common of diabetes complications is that wounds of diabetic patients tend to heal more slowly or non-healed at all, leading to undesirable facts. Diabetic wounds if become chronic and infected could provoke lower extremities amputation, sepsis even death. Hence, early detection, careful examination, debridement, cleaning, and prevention or controlling the infection of diabetic wounds are important factors for the successful outcome of the case. During the years, various promising wound dressings incorporating antimicrobial molecules, growth factors, and wound healing agents have been developed, targeting diabetic wounds. Nonetheless, the choice of dressing is mainly based on the experience of each clinician. Summary: This review summarizes the main points of diabetes complications, diabetic wounds, and infections. In further, an overview of the current drug delivery systems for topical wound delivery of various active ingredients has been performed. This update could be helpful for scientists and especially clinicians who desire to plan and work with new strategies for the healing of diabetic wounds.


2012 ◽  
Vol 49 (1) ◽  
pp. 16-23 ◽  
Author(s):  
C.I. Günter ◽  
H.-G. Machens

Author(s):  
Rick L. Vaughn ◽  
Shailendra K. Saxena ◽  
John G. Sharp

We have developed an intestinal wound model that includes surgical construction of an ileo-cecal patch to study the complex process of intestinal wound healing. This allows approximation of ileal mucosa to the cecal serosa and facilitates regeneration of ileal mucosa onto the serosal surface of the cecum. The regeneration of ileal mucosa can then be evaluated at different times. The wound model also allows us to determine the rate of intestinal regeneration for a known size of intestinal wound and can be compared in different situations (e.g. with and without EGF and Peyer’s patches).At the light microscopic level it appeared that epithelial cells involved in regeneration of ileal mucosa originated from the enlarged crypts adjacent to the intestinal wound and migrated in an orderly fashion onto the serosal surface of the cecum. The migrating epithelial cells later formed crypts and villi by the process of invagination and evagination respectively. There were also signs of proliferation of smooth muscles underneath the migratory epithelial cells.


2020 ◽  
Vol 134 (16) ◽  
pp. 2189-2201
Author(s):  
Jessica P.E. Davis ◽  
Stephen H. Caldwell

Abstract Fibrosis results from a disordered wound healing response within the liver with activated hepatic stellate cells laying down dense, collagen-rich extracellular matrix that eventually restricts liver hepatic synthetic function and causes increased sinusoidal resistance. The end result of progressive fibrosis, cirrhosis, is associated with significant morbidity and mortality as well as tremendous economic burden. Fibrosis can be conceptualized as an aberrant wound healing response analogous to a chronic ankle sprain that is driven by chronic liver injury commonly over decades. Two unique aspects of hepatic fibrosis – the chronic nature of insult required and the liver’s unique ability to regenerate – give an opportunity for pharmacologic intervention to stop or slow the pace of fibrosis in patients early in the course of their liver disease. Two potential biologic mechanisms link together hemostasis and fibrosis: focal parenchymal extinction and direct stellate cell activation by thrombin and Factor Xa. Available translational research further supports the role of thrombosis in fibrosis. In this review, we will summarize what is known about the convergence of hemostatic changes and hepatic fibrosis in chronic liver disease and present current preclinical and clinical data exploring the relationship between the two. We will also present clinical trial data that underscores the potential use of anticoagulant therapy as an antifibrotic factor in liver disease.


2006 ◽  
Vol 40 (11) ◽  
pp. 12
Author(s):  
HEIDI SPLETE

Sign in / Sign up

Export Citation Format

Share Document